Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 0.60 |
| ▸ | AKT2 | P31751 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379406 | 0.80 | RECQL (0.49) | CYP2C9CYP2C19 | |
| SCHEMBL4642962 | 0.77 | CHRM4 (0.53) | ROCK2CYP2C9CYP2C19 | |
| SCHEMBL4640871 | 0.76 | CYP2C9 (0.54) | ROCK2CYP2C9CYP2C19ROCK1 | |
| SCHEMBL3245134 | 0.76 | ROCK2 (0.79) | ROCK2 | |
| SCHEMBL3244603 | 0.76 | ROCK2 (0.58) | ROCK2ROCK1 | |
| SCHEMBL3248267 | 0.75 | ROCK2 (0.66) | ROCK2ROCK1 | |
| SCHEMBL3249722 | 0.75 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL3245013 | 0.75 | ROCK2 (0.80) | ROCK2 | |
| SCHEMBL8245493 | 0.75 | LMNA (0.64) | CYP2C9CYP2C19 | |
| SCHEMBL25546132 | 0.75 | TPSAB1 (0.63) | CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | ROCK2 727/4885AKT2 91/4885CYP2C9 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.